Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion.
Researchers found how tumors use lactate to suppress immune defenses, revealing a new target to help immunotherapy work better.
This study published in Immunity identifies a direct molecular interaction between tumor-produced lactate and the innate immune sensor STING, mechanistically explaining how metabolic reprogramming in the tumor microenvironment suppresses immune surveillance. This discovery reveals a novel therapeutic vulnerability—targeting the lactate-STING axis—that could enhance the efficacy of immunotherapy across multiple cancer types.
What the study was
- Study design
- Mechanistic preclinical study
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Immunity
Why it surfaced
Top-tier Immunity publication; identifies novel direct lactate-STING binding mechanism not previously described; major therapeutic implications for combining metabolic targeting with immunotherapy; two-year development suggesting thorough validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.